Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|November 16, 2018
EMA Suspends Authorizations of Quinolone and Fluoroquinolone Antibiotics
Author(s)Pharmaceutical Technology Editors
After a review of serious side effects, the agency decided to suspend marketing authorizations for quinolone and fluoroquinolone antibiotics and restrict use of remaining fluoroquinolone antibiotics.
Advertisement
The European Medicines Agency announced on Nov. 16, 2018 that it is suspending marketing authorization of medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid and restricting use of remaining fluoroquinolone antibiotics after a review of serious and potentially permanent side effects.
According to EMA’s human medicines committee (CHMP), prescribing information will include the potential serious side effects. Patients will be advised to stop using the antibiotic if side effects involving muscles, tendons, joints, or the nervous system occur.
CHMP is restricting the use of fluoroquinolone antibiotics. They should not be used to treat infections that are not severe, non-bacterial infections, reoccurring lower urinary tract infections, or mild or moderate bacterial infections that can be treated by other antibiotics, or to prevent traveler’s diarrhea. Fluoroquinolones, according to EMA, should be avoided in patients with previous occurrences of side effects, and special caution should be used when treating elderly patients or those with kidney disease.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement